Evidence map›Paper›PMID 31189406›Full record

ArticleCirculation. Cardiovascular quality and outcomes2019

Integrating Quality of Life and Survival Outcomes in Cardiovascular Clinical Trials.

Jacob V Spertus, Laura A Hatfield, David J Cohen, Suzanne V Arnold, Martin Ho, Philip G Jones, Martin Leon, Bram Zuckerman, John A Spertus

Erratum issuedOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in Circulation. Cardiovascular quality and outcomes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. A Framework for the Estimation of Quality-Adjusted Life-Years Using Joint Models of Longitudinal and Survival Data.Medical decision making : an international journal of the Society for Medical Decision Making · 2026
    Article
  5. Review
  6. Article
  7. Definitions and standardized endpoints for the use of drug-coated balloon in coronary artery disease: consensus document of the Drug Coated Balloon Academic Research Consortium.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Article
  8. Future of Patient-Reported Outcomes: Bringing Patients' Voices Into Health Care.Circulation. Cardiovascular quality and outcomes · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Novel Trial Design: CHIEF-HF.Circulation. Heart failure · 2021
    Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jacob V SpertusDepartment of Statistics, University of California, Berkeley (J.V.S.).
Laura A HatfieldDepartment of Health Care Policy, Harvard Medical School, Boston, MA (L.A.H.).
David J CohenSaint Luke's Mid America Heart Institute, Kansas City MO (D.J.C., S.V.A., P.G.J., J.A.S.).
Suzanne V ArnoldSaint Luke's Mid America Heart Institute, Kansas City MO (D.J.C., S.V.A., P.G.J., J.A.S.).
Martin HoCenter for Devices and Radiologic Health, Food and Drug Administration, Bethesda MD (M.H., B.Z.).
Philip G JonesSaint Luke's Mid America Heart Institute, Kansas City MO (D.J.C., S.V.A., P.G.J., J.A.S.).
Martin LeonDivision of Cardiology, Columbia University, New York, NY (M.L.).
Bram ZuckermanCenter for Devices and Radiologic Health, Food and Drug Administration, Bethesda MD (M.H., B.Z.).
John A SpertusSaint Luke's Mid America Heart Institute, Kansas City MO (D.J.C., S.V.A., P.G.J., J.A.S.).
Saint Luke's Hospital · USCenter for Devices and Radiological Health · USColumbia University Irving Medical Center · USHarvard University · US

Funding

Optimal Decision Making in Aortic Valve ReplacementK23HL116799 · NHLBI · SAINT LUKE'S HOSPITAL · PI ARNOLD, SUZANNE VICTORIA · 2014 to 2018
$635k
NHLBI NIH HHS K23 HL116799
6 · The paper itself

Abstract

Background Survival and health status (eg, symptoms and quality of life) are key outcomes in clinical trials of heart failure treatment. However, health status can only be recorded on survivors, potentially biasing treatment effect estimates when there is differential survival across treatment groups. Joint modeling of survival and health status can address this bias. Methods and Results We analyzed patient-level data from the PARTNER 1B trial (Placement of Aortic Transcatheter Valves) of transcatheter aortic valve replacement versus standard care. Health status was quantified with the Kansas City Cardiomyopathy Questionnaire (KCCQ) at randomization, 1, 6, and 12 months. We compared hazard ratios for survival and mean differences in KCCQ scores at 12 months using several models: the original growth curve model for KCCQ scores (ignoring death), separate Bayesian models for survival and KCCQ scores, and a Bayesian joint longitudinal-survival model fit to either 12 or 30 months of survival follow-up. The benefit of transcatheter aortic valve replacement on 12-month KCCQ scores was greatest in the joint-model fit to all survival data (mean difference, 33.7 points; 95% credible intervals [CrI], 24.2-42.4), followed by the joint-model fit to 12 months of survival follow-up (32.3 points; 95% CrI, 22.5-41.5), a Bayesian model without integrating death (30.4 points; 95% CrI, 21.4-39.3), and the original growth curve model (26.0 points; 95% CI, 18.7-33.3). At 12 months, the survival benefit of transcatheter aortic valve replacement was also greater in the joint model (hazard ratio, 0.50; 95% CrI, 0.32-0.73) than in the nonjoint Bayesian model (0.54; 95% CrI, 0.37-0.75) or the original Kaplan-Meier estimate (0.55; 95% CI, 0.40-0.74). Conclusions In patients with severe symptomatic aortic stenosis and prohibitive surgical risk, the estimated benefits of transcatheter aortic valve replacement on survival and health status compared with standard care were greater in joint Bayesian models than other approaches.

Indexed as

Health StatusPatient Reported Outcome MeasuresQuality of LifeRandomized Controlled Trials as TopicResearch DesignTranscatheter Aortic Valve ReplacementAgedAged, 80 and overAortic Valve StenosisBayes TheoremEndpoint DeterminationFemaleHumansKaplan-Meier EstimateMaleRecovery of Functionhealth statusheart failurequality of liferisktranscatheter aortic valve replacement

Identifiers

PMID31189406
PMCPMC6579042
OpenAlexW2951636570

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.